Section Arrow
ENGN.NASDAQ
- enGene Holdings
Quotes are at least 15-min delayed:2026/01/09 14:16 EST
Regular Hours
Last
 8.88
+0.38 (+4.47%)
Day High 
8.9795 
Prev. Close
8.5 
1-M High
10.1 
Volume 
174.47K 
Bid
8.85
Ask
8.99
Day Low
8.39 
Open
8.54 
1-M Low
7.57 
Market Cap 
569.37M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 8.88 
20-SMA 8.68 
50-SMA 7.98 
52-W High 11.14 
52-W Low 2.65 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.29/-1.81
Enterprise Value
591.15M
Balance Sheet
Book Value Per Share
2.50
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4584+0.074+19.25%-- 
ASBPAspire Biopharma Holdings Inc.0.100101-0.003199-3.10%-- 
SLSSELLAS Life Sciences Group3.32-0.54-13.99%-- 
ARDXArdelyx7.65+0.65+9.29%-- 
IBIOiBio2.585+0.235+10.00%0.65PE
Industry overview quotes are at least 15 minutes delayed
Business Description
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.